AstraZeneca Mulls Appeal After Australian Federal Court Rules Crestor Patents Invalid
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca mulls an appeal of an Australian Federal Court judge’s ruling on Crestor patents as the anti-cholesterol drug faces a patent cliff worldwide.
You may also be interested in...
AstraZeneca’s Executive Shakeup Includes Global Strategist To Be Named Later
AstraZeneca's new CEO Pascal Soriot signaled significant change is afoot for the troubled drug maker by eliminating the jobs of R&D President Martin Mackay and Exec VP-Global Commercial Tony Zook.
As Crestor Patent Trial Nears, Generic Firms Seek To Block AstraZeneca Subsidiary From Suit
Defendants in infringement case claim AstraZeneca Pharmaceuticals LP has no rights to the patent at issue.
Cynata Sets Stage For Global Fujifilm Cell Therapy Deal
Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.